NASDAQ:ZURA Zura Bio Q3 2026 Earnings Results & Report $4.04 +0.19 (+4.94%) Closing price 10/30/2026 04:00 PM EasternExtended Trading$4.01 -0.03 (-0.67%) As of 10/30/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zura Bio beat analyst earnings expectations in its Q3 2026 results, released October 27, 2026. The company reported EPS of -$0.20 versus the -$0.2039 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateOctober 27, 2026TimeBefore Market OpensConference Call7:00 AM ET Zura Bio EPS ResultsActual EPS-$0.20Consensus EPS -$0.2039Beat/MissBeat by +$0.0039One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersZura Bio Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsZura Bio's Q4 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zura Bio Q3 2026 Earnings FAQ Did Zura Bio beat earnings estimates for Q3 2026? Zura Bio (NASDAQ:ZURA) reported earnings of -$0.20 per share for Q3 2026, beating the consensus estimate of -$0.2039. The report was announced on Tuesday, October 27, 2026. When is Zura Bio's next earnings date? Zura Bio's next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zura Bio on the company's earnings history page. Zura Bio Earnings HeadlinesBiotech Stocks Move Higher: ZURA Surges 21%, PLUR Gains 13%, WVE Rises 7%, KNSA AdvancesOctober 28 at 10:08 AM | rttnews.comStock Traders Buy Large Volume of Call Options on Zura Bio (NASDAQ:ZURA)October 28 at 1:41 AM | americanbankingnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business.October 31 at 1:00 AM | Porter & Company (Ad)Zura Bio Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026October 27, 2026 | marketscreener.comMZura Bio Limited reports third quarter 2026 financial resultsOctober 27, 2026 | msn.comZura Bio Reports $25.8 Million Third-Quarter 2026 Net LossOctober 27, 2026 | quiverquant.comQSee More Zura Bio Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zura Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zura Bio and other key companies, straight to your email. Email Address About Zura BioZura Bio (NASDAQ:ZURA), Ltd. is a clinical-stage biotechnology company focused on developing medicines for immune-mediated diseases. The company’s research and development programs are designed to address conditions in which abnormal immune-system activity contributes to inflammation and tissue damage. Zura Bio’s lead investigational product, ZT-101, formerly known as ZB-106 or tibulizumab, is a dual-antagonist antibody designed to inhibit signaling associated with interleukin-17A and B-cell activating factor. The company has studied or advanced the program for potential use in inflammatory conditions including hidradenitis suppurativa, psoriatic arthritis and axial spondyloarthritis. The company is headquartered in the United States and trades on the Nasdaq under the symbol ZURA. Zura Bio became a publicly traded company in 2023 through a business combination with JATT Acquisition Corp. As a clinical-stage biotechnology company, its therapies remain investigational and are subject to clinical testing and regulatory review before they could become commercially available.View Zura Bio ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Silicon Shock: Intel's 25% Valuation ResetMarketBeat Week in Review – 10/26 - 10/30DoorDash's $17 Billion Bet on Instacart Faces a Long Regulatory Road AheadAmazon's Record Margins Couldn't Stop the Sell-Off—Here's WhyStarbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?Breaching the Valuation: The Real Reason Fortinet Dropped Upcoming Earnings Marriott International (11/2/2026)Diamondback Energy (11/2/2026)Williams Companies (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Realty Income (11/2/2026)Apple (11/2/2026)Palantir Technologies (11/2/2026)Entergy (11/2/2026)Booking (11/3/2026)Ferrari (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
